About Fibulin-5
Fibulin-5 (FBLN5) is a protein
from Homo sapiens identified by UniProt accession
Q9UBX5, 448 residues long.
MolForge cross-references it against 0 known binders and
248 disease associations.
Target properties
| Protein name | Fibulin-5 |
| UniProt accession | Q9UBX5 |
| Gene | FBLN5 |
| Organism | Homo sapiens |
| Length | 448 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (248)
Diseases linked to this target (Open Targets).
- cutis laxa, autosomal recessive, type 1A · score 0.75
- macular degeneration, age-related, 3 · score 0.74
- Charcot-Marie-Tooth disease, demyelinating, IIA 1H · score 0.73
- age-related macular degeneration · score 0.62
- autosomal recessive cutis laxa type 1 · score 0.60
- cutis laxa, autosomal dominant 2 · score 0.59
- autosomal dominant cutis laxa · score 0.41
- hereditary sensorimotor neuropathy with hyperelastic skin · score 0.40
- pulse pressure measurement · score 0.39
- blood protein measurement · score 0.30
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9UBX5-F1 | alphafold | PREDICTED | 83.34 | — |
Amino-acid sequence (448 residues)
MPGIKRILTV TILALCLPSP GNAQAQCTNG FDLDRQSGQC LDIDECRTIP EACRGDMMCV NQNGGYLCIP RTNPVYRGPY SNPYSTPYSG PYPAAAPPLS APNYPTISRP LICRFGYQMD ESNQCVDVDE CATDSHQCNP TQICINTEGG YTCSCTDGYW LLEGQCLDID ECRYGYCQQL CANVPGSYSC TCNPGFTLNE DGRSCQDVNE CATENPCVQT CVNTYGSFIC RCDPGYELEE DGVHCSDMDE CSFSEFLCQH ECVNQPGTYF CSCPPGYILL DDNRSCQDIN ECEHRNHTCN LQQTCYNLQG GFKCIDPIRC EEPYLRISDN RCMCPAENPG CRDQPFTILY RDMDVVSGRS VPADIFQMQA TTRYPGAYYI FQIKSGNEGR EFYMRQTGPI SATLVMTRPI KGPREIQLDL EMITVNTVIN FRGSSVIRLR IYVSQYPF
Explore Fibulin-5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets